Forget the pronouncements from Washington; what this policy shift means is that your next life-saving drug or breakthrough technology might not come from the US anymore. It’s about where the next big ideas will originate and who will profit from them.
Washington appears to be flirting with a dangerous idea: a return to government-led industrial policy. This isn’t a hypothetical; it’s a tangible pivot away from the foundational principles that propelled the United States to global technological leadership for decades. The implications for real people—scientists, entrepreneurs, and ultimately, consumers—are profound, and frankly, a bit chilling.
When government industrial policy gets it wrong, the result is catastrophic. When decentralization gets it wrong, the losses are paid by entrepreneurs, not all of society.
Remember the era before 1980? Basic research, funded by Uncle Sam, churned out incredible discoveries, but they mostly languished in university labs. The critical bridge from scientific curiosity to market reality was missing. Vannevar Bush, in his seminal Science, the Endless Frontier, laid out a vision for federal support of basic research, but the translation into economic power remained elusive.
That all changed with the Bayh-Dole Act. Suddenly, those who did the federally funded research could own the resulting patents. This injected a potent dose of private-sector incentive into the innovation pipeline. It wasn’t about picking winners and losers from Washington; it was about empowering the innovators themselves. The results, as The Economist so aptly put it, were “Possibly the most inspired piece of legislation over the past half century.” America rocketed back to the forefront, leaving centralized industrial policy models, like Japan’s at the time, struggling to keep pace.
Is This a Backwards Slide?
Now, facing renewed competition from China, Washington seems intent on rewriting the rules. A recent Wall Street Journal headline captures the unsettling shift: “Washington Rewrites the Rule of Funding Technological Innovation.” The piece highlights a move “giving priority to private-sector research over basic science.” This isn’t a subtle course correction; it’s a declared departure from the strategy that delivered decades of American ingenuity and economic growth.
So, what’s driving this? Fear. Fear of falling behind China, fear of losing manufacturing, and a misunderstanding of what made us strong in the first place. It’s a classic case of chasing symptoms instead of addressing the root cause.
Here’s the kicker: China, rather than replicating our perceived strengths, is doubling down on ours. Xi Jinping has made “the gutsy and perhaps counterintuitive decision to invest massively in an arena of American strength—basic research.” The Covid pandemic, exposing vulnerabilities in supply chains and R&D dependencies, accelerated this strategic pivot. While Western researchers developed high-efficacy vaccines rapidly, China’s R&D infrastructure lagged. Now, they’re not just playing catch-up; they’re aiming to lead.
“China is rallying their innovation to degrees that we haven’t seen before,” Pfizer Chief Executive Albert Bourla said.
This isn’t just about pharmaceuticals, either. China’s biotechnology sector is exploding, with researchers and startups on the cutting edge of molecular biology, developing new treatments for cancer and other diseases. Major drugmakers and investors are pouring billions into Chinese drug candidates, recognizing the burgeoning innovation there. Meanwhile, the US appears to be… what? Slowing down?
The Growing Misuse of OTAs
The concern deepens when you look at the mechanisms being employed. Agencies are increasingly shifting from grants—the bedrock of the Bayh-Dole system—to “other transaction agreements” (OTAs). Why does this matter? Because OTAs operate outside the scope of Bayh-Dole, meaning the patent rights provisions that fueled American innovation don’t necessarily apply. This is a deliberate move to sidestep the very law that made us great, creating a legal loophole that benefits neither the researchers nor the public interest in the long run.
It feels like a short-sighted attempt to force innovation by decree, rather than fostering an environment where it can organically flourish. This isn’t about picking specific technologies to back; it’s about dismantling the framework that enables the spontaneous emergence of world-changing discoveries. The historical parallel is stark: centrally planned economies always falter against decentralized, incentivized innovation. This latest policy gambit risks repeating that error.
This is more than just a policy debate; it’s an existential question for American innovation. If we abdicate our leadership in basic research and weaken the patent incentives that drive commercialization, we’re not just falling behind; we’re actively dismantling our own competitive advantage. The siren’s call of industrial policy, promising quick wins, is leading us away from the proven path of decentralized, incentivized discovery. Let’s hope cooler heads, and a deeper understanding of what truly drives innovation, prevail.
🧬 Related Insights
- Read more: EFF to Supreme Court: Cisco Built China’s Torture Machine—Time to Pay Up
- Read more: Jones Day Hacked Again: Social Engineering Exposes Elite Law Firm’s Vulnerabilities
Frequently Asked Questions
What does the Bayh-Dole Act do?
The Bayh-Dole Act of 1980 allows universities, small businesses, and non-profits to retain intellectual property rights (patents) for inventions developed with federal funding. This incentivizes them to commercialize these discoveries.
Why is shifting away from basic research a concern?
Basic research is fundamental for unpredictable, breakthrough discoveries. Prioritizing applied or private-sector research over basic science risks stifling the foundational innovations that drive long-term economic growth and technological advancement.
Will OTAs replace grants entirely?
It’s unlikely OTAs will entirely replace grants, as they serve different purposes and have different regulatory frameworks. However, the increasing reliance on OTAs for research funding, particularly when they circumvent Bayh-Dole provisions, raises concerns about the future of university-industry technology transfer.
